MED vs UTZ

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

MED

39.2
AI Score
VS
UTZ Wins

UTZ

57.4
AI Score

Investment Advisor Scores

MED

39score
Recommendation
SELL

UTZ

57score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED UTZ Winner
Revenue 224.48M 1.10B UTZ
Net Income -22.73M -36.10M MED
Gross Margin 69.1% 24.1% MED
Net Margin -10.1% -3.3% UTZ
Operating Income -26.98M -19.40M UTZ
ROE -12.6% -5.3% UTZ
ROA -9.5% -1.3% UTZ
Total Assets 239.76M 2.78B UTZ
Cash 58.37M 70.10M UTZ
Current Ratio 4.82 1.07 MED
Free Cash Flow 2.76M -48.90M MED

Relative Price Performance (Last 90 Days)

MED 1M: +12.5% · 3M: +14.4% UTZ 1M: -0.3% · 3M: +0.6%

Current Technical Phase

MED

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 62

RSI (14): 62.0 · Price: $13.13

UTZ

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 43

RSI (14): 43.4 · Price: $14.25

Fundamentals Snapshot

Metric MED UTZ
Market Cap — —
Forward P/E -328.3 18.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% 0.0%
Gross Margin 0.7% 0.2%
Operating Margin -0.3% 0.0%
EPS -3.70 -0.44
Dividend Yield — 0.03%

Frequently Asked Questions

Based on our detailed analysis, UTZ is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.